Lv2
150 积分 2023-04-11 加入
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
[Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)]
3个月前
已完结
Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm
6个月前
已完结
Tardive Dyskinesia with Antipsychotic Medication in Children and Adolescents: A Systematic Literature Review
6个月前
已完结
Shedding light on FGF21: A potential negative regulator of PCSK9
7个月前
已完结
Severe hypertriglyceridemia: Existing and emerging therapies
7个月前
已完结
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
7个月前
已完结
Pegozafermin led to significant metabolic benefits, in addition to robust beneficial effects on the liver, in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)
7个月前
已完结
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study
7个月前
已完结
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
9个月前
已完结
皖公网安备34019202002308
